Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 12, 2005, Pages 4950-4956

  Nakayama, Hector ^a   Loiseau, Philippe M ^b   Bories, Christian ^b   Torres De Ortiz, Susana ^a   Schinini, Alicia ^a   Serna, Elsa ^a   Rojas De Arias, Antonieta ^a   Fakhfakh, Mohamed A ^b   Franck, Xavier ^b   Figadère, Bruno ^b   Hocquemiller, Reynald ^b   Fournet, Alain ^c  

^a UNIVERSIDAD NACIONAL DE ASUNCIÓN   (Paraguay)

^b UNIVERSITÉ PARIS SUD   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 N PROPYLQUINOLINE; AMPHOTERICIN B; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; QUINOLINE DERIVATIVE; SITAMAQUINE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; LEISHMANIA; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN LEISHMANIASIS; SPLEEN; SUPERINFECTION; VISCERAL LEISHMANIASIS;

EID: 28844432327     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.12.4950-4956.2005     Document Type: Article

References (28)

1. Arevalo, I., B. Ward, R. Miller, T. C. Meng, E. Najar, E. Alvarez, G. Matlashewski, and A. Llanos-Cuentas. 2001. Successful treatment of drug-resistant cutaneous leishmaniasis in human by use of imiquimod, an immunomodulator. Clin. Infect. Dis. 33:1847-1851.
2. Armijos, R. X., M. M. Weigel, M. Calvopina, M. Mancheno, and R. Rodriguez. 2004. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop. 91:153-160.
3. Belliard, A. M., B. Baune, M. Fakhfakh, R. Hocquemiller, and R. Farinotti. 2003. Determination of the human cytochrome P 450 involved in the metabolism of 2-n-propylquinoline. Xenobiotica 33:341-355.
4. Belliard, A. M., C. Leroy, H. Banide, R. Farinotti, and B. Lacour. 2003. Decrease of intestinal P-glycoprotein activity by 2n-propylquinoline, a new oral treatment for visceral leishmaniasis. Exp. Parasitol. 103:51-56.
5. Buates, S., and G. Matlashewski. 2001. Identification of genes induced by a macrophage activator, S-28463, using gene expression array analysis. Antimicrob. Agents Chemother. 45:1137-1142.
6. Buffet, P. A., A. Sulahan, Y. J. F. Garin, N. Nassar, and F. Derouin. 1995. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissue of infected mice. Antimicrob. Agents Chemother. 39:2167-2168.
7. Croft, S. L., and G. H. Coombs. 2003. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 19:502-508.
8. Desjeux, P. 1998. UNAIDS. Leishmania and HIV in gridlock. WHO and UN programme on HIV/AIDS; WHO/CTD/LEISH/98.9. World Health Organization, Geneva, Switzerland.
9. Fakhfakh, M., A. Fournet, E. Prina, J. F. Mouscadet, X. Franck, R. Hocquemiller, and B. Figadère. 2003. Synthesis and biological evaluation of substituted quinolines: potential treatment of protozoal and retroviral coinfections. Bioorg. Med. Chem. 11:5013-5023.
10. Fournet, A., M. E. Ferreira, S. Torres de Ortiz, S. Fuentes, H. Nakayama, A. Rojas de Arias, A. Schinini, and R. Hocquemiller. 1996. In vivo efficacy of 2-substituted quinolines in experimental treatment of New World cutaneous leishmaniasis caused by Leishmania amazonensis. Antimicrob. Agents Chemother. 40:2447-2451.
11. Fournet, A., J. C. Gantier, A. Gautheret, L. Leysalles, M. H. Munos, J. Mayrargue, H. Moskowitz, A. Cavé, and R. Hocquemiller. 1994. The activity of 2-substituted quinoline alkaloids in BALB/c mice infected with Leishmania donovani. J. Antimicrob. Chemother. 33:537-544.
12. Fournet, A., M. Mahieux, M. A. Fakhfakh, X. Franck, R. Hocquemiller, and B. Figadère. 2003. Substituted quinolines induce inhibition of proliferation of HTLV-1 infected cells. Bioorg. Med. Chem. Lett. 13:891-894.
13. Franck, X., A. Fournet, E. Prina, R. Mahieux, R. Hocquemiller, and B. Figadère. 2004. Biological evaluation of substituted quinolines. Bioorg. Med. Chem. Lett. 14:3635-3638.
14. Gantier, J. C., A. Fournet, M. H. Munos, and R. Hocquemiller. 1996. The effect of some 2-substituted quinolines isolated from Galipea longiflora on Plasmodium vinckei petteri infected mice. Planta Med. 62:285-286.
15. Garin, Y. J. F., A., Sulahian, F. Pratlong, P. Méneceur, J. P. Gangneux, E. Prina, J. P. Dedet, and F. Derouin. 2001. Virulence of Leishmania infantum is expressed as a clonal and dominant phenotype in experimental infections. Infect. Immun. 69:7365-7373.
16. Guerin, P. J., P. Olliaro, S. Sundar, M. Boelaert, S. L. Croft, P. Desjeux, M. K. Wasunna, and A. D. Bryceson. 2002. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect. Dis. 2:494-501.
17. Iglarz, M., B. Baune, J. C. Gantier, R. Hocquemiller, and R. Farinotti. 1998. Determination of 2-n-propylquinoline in mouse plasma and liver by HPLC J. Chromatogr. B 714:335-340.
18. Langreth, S. G., J. D. Berman, G. P. Riordan, and L. S. Lee. 1983. Fine-structural alterations in Leishmania tropica within human macrophages exposed to antileishmanial drugs in vitro. J. Protozool. 30:555-561.
19. Loiseau, P. M., L. Imbertie, C. Bories, D. Beteder, and I. De Miguel. 2002. Design and antileishmanial activity of amphotericin B-loaded stable ionic amphiphile biovector fomulations. Antimicrob. Agents Chemother. 46:1597-1601.
20. Nakayama, H., M. E. Ferreira, A. Rojas de Arias, N. V. de Bilbao, A. Schinini, and A. Fournet. 2001. Experimental treatment of chronic Trypanosoma cruzi infection in mice with 2-n-propylquinoline. Phytother. Res. 15:630-632.
21. Perez-Victoria, J. M., A. Di Pietro, D. Barron, A. G. Ravelo, S. Castanys, and F. Gamarro. 2002. Multidrug resistance phenotype mediated by the P-glycoprotein-like transporter in Leishmania: a search for reversal agents. Curr. Drug Targets 3:311-333.
22. Stauber, L. A., E. M. Franchino, and J. Grun. 1958. An eight-day method for screening compounds against Leishmania donovani in the golden hamster. J. Protozool. 5:269-273.
23. Sundar, S., and H. W. Murray. 2005. Availability of miltefosine for the treatment of kala-azar in India. Bull. W. H. O. 83:394-395.
24. Sundar, S., T. K. Jha, C. P. Thakur, J. Engel, H. Sindermann, C. Fisher, K. Junge, A. Bryceson, and J. Berman. 2002. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. 347:1739-1746.
25. Vercesi, A. E., and R. Docampo. 1992. Ca2+ transport by digitonin-permeabilized Leishmania donovani. Effects of Ca2+, pentamidine and WR-6026 on mitochondrial membrane potential in situ. Biochem. J. 284:463-467.
26. Vercesi, A. E., C. O. Rodrigues, R. Catisti, and R. Docampo. 2000. Presence of a Na(+)/H(+) exchanger in acidocalcisomes of Leishmania donovani and their alkalization by anti-leishmanial drugs. FEBS Lett. 473:203-206.
27. Yeates, C. 2002. Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute). Curr. Opin. Investig. Drugs 3:1446-1452.
28. Zouhiri, F., J. F. Mouscadet, K. Mekouar, D. Desmaele, D. Savouré, H. Leh, F. Subra, M. Le Bret, C. Auclair, and J. d'Angelo, 2000. Structure-activity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture. J. Med. Chem. 43:1533-1540.